Sustainability

AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Biotech

Eos Energy posts 351% revenue jump but narrows 2026 guidance

The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on
The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on
The Biotech Times Editorial Team  · 
AgriTech
Digital Health
Bioinformatics

BCC Research: AI set to reshape carbon farming verification market

A new BCC Research report says AI-driven MRV tools are drawing significant VC interest as voluntary carbon markets face mounting credibility pressure.
A new BCC Research report says AI-driven MRV tools are drawing significant VC interest as voluntary carbon markets face mounting credibility pressure.
The Biotech Times Editorial Team  · 
Digital Health

Startup Coalition and DSIT launch Pitch in Whitehall competition

UK startups have until 24 July to apply for a government proof-of-concept contract under the Green Compute challenge.
UK startups have until 24 July to apply for a government proof-of-concept contract under the Green Compute challenge.
The Biotech Times Editorial Team  · 
Biotech

HCLTech selected as IT transformation partner by Neste

HCLTech will lead IT service consolidation and AI-driven efficiency improvements for Neste as part of the Finnish renewables firm's performance programme.
HCLTech will lead IT service consolidation and AI-driven efficiency improvements for Neste as part of the Finnish renewables firm's performance programme.
The Biotech Times Editorial Team  · 
Biotech

Actuate Therapeutics names Martin Huber to board of directors

The NASDAQ-listed oncology biotech has appointed the former Mersana Therapeutics CEO as an independent director to support elraglusib's path to registration studies.
The NASDAQ-listed oncology biotech has appointed the former Mersana Therapeutics CEO as an independent director to support elraglusib's path to registration studies.
The Biotech Times Editorial Team  · 
Subscribe to Sustainability